Institute of Environmental Medicine and
Kaplan Comprehensive Cancer Center, New York University Medical
Center, New York, New York 10016
Received 13 July 1998/Returned for modification 2 September
1998/Accepted 7 January 1999
The cytosine analog 5-azacytidine (5-AzaC) is a demethylating agent
that is also known to induce mutagenesis in mammalian cells. In this
study, the mutagenic potential of this drug was tested in the G10 and
G12 transgenic Chinese hamster cell lines, which have a single
bacterial gpt gene integrated into the genome at different
sites, with its expression driven by a simian virus 40 (SV40) promoter.
We show that the mutation frequencies following a 48-h exposure to
different concentrations of 5-AzaC were 10 to 20 times higher than
those of any of the other numerous mutagens that have been tested in
the G10-G12 system. Moreover, the mutation frequencies were much higher
in the G10 cell line than in the G12 cells. Detailed molecular analysis
of the 6-thioguanine (6-TG)-resistant variants demonstrated that
transgene silencing by de novo DNA methylation and increased chromatin
condensation in the SV40 promoter was the major factor responsible for
this high level of 6-TG resistance. As would be expected, exposure to
5-AzaC lowered the overall genomic DNA methylation levels, but
it unexpectedly caused hypermethylation and increased chromatin
condensation of the transgene in both the G10 and G12 cell lines. These
results provide the first evidence that 5-AzaC may also induce
transgene-specific DNA methylation, a phenomenon that can further be
used for the elucidation of the mechanism that controls silencing of
foreign DNA.
 |
INTRODUCTION |
Transfection of exogenous marker
genes into mammalian cells and integration of those genes into the
mammalian genome facilitate the study of factors affecting mutagenesis
and gene expression (25). G10 and G12 are two transgenic
gpt+ hprt
V79 cell lines that have
been studied extensively and represent an important set of mammalian
cell lines for mutagenesis studies (19, 20). The bacterial
xanthine guanine phosphoribosyltransferase enzyme is functionally
analogous to the endogenous mammalian hypoxanthine phosphoribosyltransferase. The G10 cell line is more susceptible to
spontaneous and induced mutagenicity than is the G12 cell line. Most of
the spontaneous mutations and mutations induced by X ray or bleomycin
were characterized as deletions in the G10 cell line (21).
This was explained by the genomic mapping data that showed partial duplication of gpt-flanking plasmid sequences in G10
but not in G12 cells (21). These sequences could facilitate
homologous recombination, resulting in the observed high deletion
frequencies (21). Additionally, it is known that a single
copy of the gpt gene was integrated into each of these cell
lines on different chromosomes (22). In the G12 cell line,
the gpt gene was integrated on chromosome 1, near the
telomere and adjacent to a dense region of heterochromatin, while in
the G10 cell line, the gpt gene was integrated on chromosome
6, distant from any heterochromatin.
Unusual results were obtained for the highly carcinogenic nickel
compounds (22). Nickel subsulfide and crystalline nickel sulfide were only weakly mutagenic in G10 cells (15), but
they induced extremely high (10
3) frequencies of
6-thioguanine (6-TG) resistance in the G12 cells (22). It
was shown that the mechanism of the 6-TG resistance involved chromatin
condensation and silencing of the gpt gene by de novo DNA
methylation. The localization of the gpt sequence in the
vicinity of a dense heterochromatin area in G12 cells has been proposed
to explain the selective sensitivity of this sequence to nickel
(22). Similar DNA methylation silencing of transgenes have
been reported for gpt sequences in transfected human cell lines as a result of UV or ethyl methanesulfonate treatment (7, 23).
For evaluation of the mutagenic and epigenetic potential of other
carcinogens, a combined G10-G12 screening may be informative. In this
study, we used the G10 and G12 cell lines to analyze the mutagenic
effects of 5-azacytidine (5-AzaC). 5-AzaC is a cytosine analog that
when incorporated into DNA caused extensive demethylation of
5-methylcytosine. This was due to covalent binding of DNA
methyltransferase to 5-AzaC in DNA (14, 31) and a subsequent
reduction of the enzyme activity in the cell, as well as the
incorporation of a nonmethylating site, such as 5-AzaC, in place of the
normal base cytosine. The demethylation activity of this drug induces
muscle cell differentiation in CH3 10T1/2 or 3T3 cells (34).
Treatment of mammalian cell lines with 5-AzaC or its deoxyribose
congener 5-Aza-2'-deoxycytidine has resulted in a variety of altered
phenotypes, including changes in chromosome structure, gene expression,
and cellular morphology (29, 32), and in the induction of
apoptosis (18). Numerous investigations have described the
reactivation of de novo-methylated silenced genes by 5-Aza-CR or
5-Aza-2'-deoxycytidine. These genes include loci on the inactive X
chromosome (13), the VHL gene (9), the E-cadherin
gene (35), the estrogen receptor gene (27), and
the p16 gene (2). Silenced transgenes are also reactivated
after treatment with this drug (22, 23).
The adducts formed between DNA methyltransferase and genomic
DNA with a 5-Aza substitution (14) can sterically inhibit
DNA replication, transcription, and DNA repair and may play a role in
5-Aza-induced mutagenesis in mammalian cells (1, 3,
24). 5-AzaC is also known to be a mutagen in
Escherichia coli (6), Salmonella
typhimurium (3, 30), and Saccharomyces
cerevisiae (36).
Here we describe the molecular analysis of 6-TGr G10
and G12 variants induced by treatment with 5-AzaC and surprisingly show that in most cases the inactivation of the gpt gene was
correlated with higher DNA methylation levels of CpG islands and
increased chromatin condensation in the gpt regions in both
cell lines. Meanwhile, as expected, the overall genomic DNA
methylation levels in the variants were lower than those in the
original untreated cells. This finding may allow new approaches
for the isolation and characterization of specific regulators that
inhibit transgene expression and point to the importance of DNA
hypermethylation as a mechanism that silences foreign DNA.
 |
MATERIALS AND METHODS |
Cell culture conditions.
The gpt+
(xanthine guanine phosphoribosyltransferase gene) transgenic G10 and
G12 cells were cultured in F-12 medium (Life Technologies, Inc., GIBCO
BRL, Grand Island, N.Y.) supplemented with 5% fetal bovine serum
(GIBCO) and 1% penicillin-streptomycin (GIBCO) at 37°C in a humid
5% CO2 atmosphere. In order to maintain a low
spontaneous-mutation frequency, G10 and G12 cultures were supplemented
with hypoxanthine-aminopterin-thymidine, and fresh cultures were
defrosted every 6 weeks. One day prior to the beginning of each
mutagenesis experiment, the cells were removed from
hypoxanthine-aminopterin-thymidine selection.
5-AzaC mutagenesis assay.
A total of 5 × 105 G10 or G12 cells were seeded into 80-cm2
tissue culture flasks and after 4 to 6 h were exposed to various concentrations of 5-AzaC for 2 days. After the treatment was removed, the cells were rinsed with saline A twice and incubated in F-12 medium
for a 7-day expression period. Cytotoxicity was determined for each
treatment by plating 400 cells in each of three 6-cm dishes and
determining the clonal survival relative to untreated controls.
Following the expression period, 2 × 106 mutagenized
cells per treatment were reseeded at a maximum cell density of 2 × 105 cells/100-mm dish into F-12 containing 10 µg of
freshly prepared 6-TG per ml for 10 days. The reseeding plating
efficiency in nonselective medium (F-12) was determined for
mutation frequency calculations after 7 days of growth without
selection. The number of mutant colonies growing in the selection
medium following a correction for the number of clonable cells was used
to calculate the mutation frequency. Thus, the mutation frequency
refers to the number of cells that survived the 5-AzaC treatment.
Unstained mutant colonies were individually isolated and characterized.
Deletion screen by PCR amplification of coding sequences.
The gpt gene was amplified by the PCR method as previously
described (22). The amplification reaction mixtures (100 µl) contained 1 µg of genomic DNA (G10, G12, and
6-TGr clones), 100 pmol of amplification primers
5'-AACACTTTTTAAGCCGTAGATAAA and
5'-TATTGTAACCCGCCTGAAGTTAAA (these primers hybridize 18 bases before and 39 bases after the gpt coding region,
respectively), 200 µM deoxynucleoside triphosphate, and 2.5 U of
Taq polymerase in a 50 mM KCl-10 mM Tris (pH 8.0; 1.5 mM
MgCl2-0.01% [wt/vol] gelatin) buffer. Amplification
(typically 30 cycles) was performed in Perkin-Elmer thermal cycler. The
resultant PCR products were then separated on 1.2% agarose gels to
screen for any tentative deletions.
Genomic methylation level.
A modification of the
methyl-accepting assay (17) was used to determine the
methylation level of DNA isolated from G10, G12, and 6-TGr
cells. DNA (200 ng) was incubated with 4 U of SssI
methylases (New England Biolabs) in the presence of 1.5 µM
S-adenosyl-L-[methyl-3H]methionine
and 1.5 µM nonradioactive S-adenosylmethionine. The reaction mixtures (20 µl), in the manufacturer's buffer containing 0.1 µg of RNase A, were incubated at 37°C for 4 h. The
reactions were terminated by adding 300 µl of stop solution (1%
sodium dodecyl sulfate, 2 mM EDTA, 5% 2-propanol, 125 mM NaCl, 1 mg of
proteinase K per ml, 0.25 mg of carrier DNA per ml) for 1 h at
37°C. The DNA was extracted with phenol-chloroform and ethanol
precipitated. The recovered DNA was resuspended in 30 µl of 0.3 M
NaOH and incubated for 30 min at 37°C. DNA was spotted on Whatman
GF/C filter discs, dried, and then washed five times with 5% (wt/vol)
trichloroacetic acid followed by 70% (vol/vol) ethanol. Filters were
placed in scintillation vials and incubated for 1 h at 60°C with
500 µl of 0.5 M perchloric acid. Then 5 ml of scintillation cocktail was added and the 3H incorporation was determined by a
Beckman liquid scintillation counter. Higher levels of
[3H]methyl group incorporated into DNA indicated lower
levels of genomic DNA methylation, but when less
[3H]methyl group was incorporated, a higher level of
genomic DNA methylation was indicated (17).
DNA methylation studies with methylation-sensitive restriction
enzymes.
Ten micrograms of DNA from G10 and G12 cells and
6-TGr 5-AzaC G10 and G12 variants were first digested with
the restriction endonuclease EcoRV (5 U/µg of
genomic DNA) and then extracted with phenol-chloroform and
ethanol precipitated. This digestion released a 1.7-kb genomic
fragment in G12 DNA and a 5.3-kb genomic fragment in G10 DNA.
This DNA fragment was digested again with 5 U of the
methylation-sensitive restriction endonuclease HpaII (5'-CCGG-3'; U.S. Biochemicals) or HaeII (5'-PuGCGCPy-3';
New England Biolabs) per µg or with the insensitive isoschizomer
MspI. The digested DNA was fractionated on agarose gels,
blotted onto nylon membranes (Nytran; Schleicher & Schuell), and
hybridized with an appropriate radiolabeled probe.
Bisulfite genomic sequencing for the detection of
5-methylcytosine.
Bisulfite genomic sequencing was
performed as described by Clark et al. (5) with the
modifications described by Singal et al. (32). The primers
for the PCR amplification (5'-ACATAAATCTACAACATATCCCAAATAACA/GATA and 5'-ATGTAAAGTATGTATTTTAATTAGTTAGTAATTA) were
constructed after the bisulfite conversion reaction had been taken into
account. (The sequence of the unmodified sense strand for which these
primers were constructed is depicted in Fig. 5.) Direct sequencing of PCR-amplified product (408 bp) was performed with an automated DNA
sequencer (Genomis Inc.).
DNase I sensitivity assay.
The procedure for the isolation
of nuclei was reported previously (22). A total of 5 × 105 nuclei in DNase I buffer (10 mM Tris-Cl [pH 7.4], 10 mM NaCl, 3 mM MgCl2, 100 µM CaCl2) were
treated with increasing amounts (0, 0.5, 1, 2, and 10 U) of DNase I
(Boehringer) in a reaction volume of 200 µl for 30 min at 25°C. The
reactions were terminated by adding equal volume of stop solution (1%
sodium dodecyl sulfate, 0.1 M NaCl, 50 mM Tris-Cl [pH 8.0], and 10 mM
EDTA) containing 1 mg of proteinase K per ml and incubated at 55°C
for 2 h. The DNA was extracted with phenol-chloroform and ethanol
precipitated. The gpt gene was amplified by PCR (50 ng/reaction; 30 cycles) with the same primers that were described above
for the deletion screen. The PCR products were separated on 1.2%
agarose gel and stained with ethidium bromide (EtBr).
 |
RESULTS |
High mutation frequencies induced by 5-AzaC in G10 and G12
cells.
Dose-response studies for 5-AzaC were performed on the G10
and G12 cell lines (Fig. 1). The cells
were grown for 48 h in the presence of the drug, and then the
survival rates and mutation frequencies of the gpt gene
(6-TGr) were determined as described in Materials and
Methods. The concentration of 5-AzaC necessary to inhibit growth by
50% was 2 µM for both cell lines. The mutation frequencies were very
high (approximately 10 to 20 times higher) compared to those of other
mutagens tested in the G10 and G12 cell lines (22); however,
there were dissimilarities between the two cell lines. The mutation
frequency in the G10 cell line was much higher than in the G12 cell
line. This level of mutagenesis (4 × 10
2) is the
highest level ever reported for this cell line. The differences between
the cell lines may be explained by the different localizations of the
gpt gene.

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 1.
Mutation frequency and cytotoxicity of 5-AzaC in G10 and
G12 cells. The cells were exposed to various concentrations of 5-AzaC
for 48 h and then incubated for a 7-day expression period. The
selection for gpt cells was then done in a
medium containing 6-TG (10 µg/ml) for 10 days. The data represent the
median values (for mutation frequencies) and the means ± standard
deviations (for survivals) of three to eight determinations. Filled
symbols and open symbols represent the mutation frequency and percent
survival, respectively. The spontaneous mutation frequencies of the G10
( ) and G12 ( ) cells were 100 and 30 per 106 surviving
cells, respectively.
|
|
Northern and deletion analysis revealed no transcript but intact
transgene existence in most of the 6-TGr cell lines.
We examined gpt-specific mRNA levels and also gpt
genomic sequences in several G10- and G12-derived cell lines
(summarized in Table 1). These and all
mutant clones described here were independently isolated from
individually treated populations of cells. As clearly seen in the
Northern blot (Fig. 2A), only the wild-type G10 and G12 cells accumulate gpt transcript. Note,
however, that in two of the G10 variants very low levels of expression of gpt transcripts were observed (variants A5 and A6 [Fig.
2A]).

View larger version (36K):
[in this window]
[in a new window]
|
FIG. 2.
Analysis of gpt transcription in several
6-TG-resistant G10 and G12 variants. (A) Northern blot analysis of
gpt transcription. Fourteen micrograms of total RNA per cell
line was fractionated on 1% agarose gels and transferred to a nylon
membrane. The membrane was hybridized with a 32P-labeled
gpt probe that was generated by random primer labeling of a
561-bp PCR product of the gpt coding region. The arrows
indicate the expected size of the gpt transcript in the G10
(top arrow) and G12 (bottom arrow) parental lines. (B) To control for
gel-loading differences, the membranes were stripped and rehybridized
with a GAPDH probe.
|
|
The results of the PCR analysis that was done in order to determine the
presence or absence of the gpt sequence are shown in Fig.
3. The frequency of deletion mutants is
very low in both cell lines (Table 1). This resembled the low level of
deletion that was found for the 6-TGr G12-derived cell
line induced by nickel (22). However, the mutagenic
spectrum found in other studies showed that transgene deletions
occurred in 20% of the spontaneous G12 mutants and in about 50% of
the X-ray- and bleomycin-induced G12 mutants (21). The
levels were even higher (up to 95%) in G10 mutant cells
(21), which were much more highly prone to gpt
deletion than G12 cells. The lower deletion level (less than the
spontaneous frequency) obtained with 5-AzaC demonstrated a unique
mechanism activated by this drug, which silences these transgenes.

View larger version (105K):
[in this window]
[in a new window]
|
FIG. 3.
Deletion screen by PCR amplification of the
gpt coding sequence in G12-derived (A) and G10-derived (B)
6-TG-resistant cell lines. PCR products were separated on 1.2% agarose
gels and stained with EtBr. The expected 561-bp PCR product is clearly
visible in the control G10 and G12 cell lines and most of the examined
variants. No products are shown in the negative control reaction (no
template DNA) (lane N). M, molecular weight markers.
|
|
Lower genomic methylation levels in the 5-AzaC-induced
variants.
The overall methylation levels were checked for a number
of the 5-AzaC G12-derived variants and compared to those of the
original G12 cell line. The genomic methylation levels, as
expected, decreased as a result of the 5-AzaC treatment (Table
2). These low genomic methylation
levels were maintained for many cell cycles because the cells were
selected for 6-TGr before isolation and genomic DNA
methylation patterns were known to be inherited.
Evidence for DNA methylation in 5-AzaC-induced variants.
As
shown in Table 1, 87% of all the 5-AzaC variants did not accumulate
gpt transcript despite having an intact transgene. In order
to check if the transgene expression had been silenced by mechanisms
involving DNA methylation, we performed two different assays. Digestion
of genomic DNA with a methylation-sensitive restriction enzyme
followed by Southern analysis of the gpt region is shown in
Fig. 4. Figure 4A shows digestion of
genomic DNA from 6-TGr G12-derived cell lines with
the methylation-sensitive restriction enzyme HaeII. There is
one cutting site in the 5' flanking region of the integrated
gpt target sequence in the G12 cell line. When G12
genomic DNA was digested with EcoRV and
HaeII, a 1.2-kb fragment would have been obtained if both
enzymes cut, or a 1.7-kb fragment would have appeared if the
HaeII site was methylated, but only EcoRV cut the
DNA (Fig. 4D). The appearance of both bands in almost all the cell
lines examined (except A18 and A19) demonstrated partial methylation of
this site. The digestion of control G12 DNA yielded the lower band
only. The results for the G10-derived cell lines, digested with the
methylation-sensitive enzyme HpaII and the enzyme
EcoRV, are shown in Fig. 4B. There are three restriction sites for methylation-sensitive HpaII restriction enzyme in
this transgene sequence (Fig. 4D). When the DNA was completely
methylated, a 5.3-kb fragment would have been observed. If the DNA was
not methylated, 5.04- and 0.15-kb fragments (and also 0.07- and 0.04-kb fragments that are not detected with the blotting conditions used) would result from the double digest. Also in this case, the appearance of intermediate bands (0.22 and 0.26 kb) together with the lower band
(for variants A2, A3, A4, A7, A8, A9, A10, A11, and A12) indicated
increased methylation. These intermediate bands are not seen in the G10
control. In the A5 and A6 variants, we could not detect intermediate
bands. In these same cell lines, low transcription levels were detected
by the Northern analysis (Fig. 2).

View larger version (58K):
[in this window]
[in a new window]
|
FIG. 4.
Methylation of the gpt gene and its flanking
sequence in G12 (A) and G10 (B and C) 5-AzaC-induced 6-TG-resistant
cell lines. Ten micrograms of EcoRV-digested DNA was further
digested with the methylation-sensitive restriction enzyme
HaeII (A) or HpaII (B). Lane C contains
EcoRV-digested DNA not subjected to digestion with the other
enzymes. (C) Digestion of G10 and the A2, A3, and A7 5-AzaC variants
with the methylation-sensitive enzyme HpaII and the
methylation-insensitive isoschizomer MspI. To better resolve
the bands, the DNA was cut with both EcoRV and
HindIII, and fragments were separated in a 1.7% agarose
gel (6 h at 55 V). The DNA was transferred to a membrane in 20× SSC
(1× SSC is 0.15 M NaCl plus 0.015 M sodium citrate). (D) Restriction
of the gpt gene on the genomic map of G12 and G10
cell lines. The fragments were separated on agarose gels (1% [A],
1.7% [B], and 1.7% [C]), transferred to nylon membranes, and then
hybridized with a 32P-labeled gpt probe. The
variants are identified as in Fig. 2. H1, H2, H3, and H4 are the first,
second, third, and fourth HpaII sites, respectively.
|
|
Figure 4C compares the digestion of the G10 and three G10 5-AzaC
variants (A2, A3, and A7) with the methylation-sensitive HpaII and the methylation-insensitive isoschizomer
MspI. (The DNA was first digested with EcoRV and
HindIII, yielding lower molecular weights than in Fig.
4B, in which the DNA was cut with only EcoRV.) A darker
470-bp band in the HpaII cut than that in the
MspI cut indicated some partial methylation at the first
HpaII site in wild-type G10 (Fig. 4D). However, there were
additional differences in the 5-AzaC-induced variants of G10 between
MspI and HpaII cutting with respect to the
presence of the 150-bp fragment in the MspI lane and not in
the HpaII lane in each variant, indicating more methylation
in the variants at the first and second HpaII sites (Fig.
4D). Additionally, there was less intensity of the 320-bp band in
the variants cut with the HpaII than in the same DNA
cut with MspI, indicating more methylation at the first
HpaII site (Fig. 4D). There was also greater intensity of
the 470- and 540-bp fragments with HpaII cutting than with
MspI cutting in the variants (i.e., a 470-bp fragment would
be present if the first HpaII site was methylated, a 540-bp
fragment would be present if the second HpaII site was
methylated, and a 580-bp fragment would be present if the third site
was methylated [Fig. 4D]).
The second assay performed was methylation analysis of the promoter
region in different 6-TGr cells by the sodium bisulfite
sequencing method (5, 32). The region examined included 408 bp of the simian virus 40 (SV40) early promoter region, which was
located 5' to the E. coli gpt gene in these transgenic cell
lines. This region contained 18 CpG sites (Fig.
5). The results for eight independent
6-TGr cell lines and two control cell lines are summarized
in Table 3. Since direct sequence of the
PCR product was performed, the data represent a population average
(5). Table 3 shows that the amount of sites methylated in
the different cell lines varies. Note that many sites are only
partially methylated. However, almost all the cell lines had some level
of methylation in the specific region tested, excluding those with some
gpt expression, A5 and A6 variants, and the wild-type G12.
The A5 and A6 cell lines showed either no methylation or partially
methylated sites, respectively. This correlated with the low levels of
transcription and undetectable methylation after digestion with
methylation-sensitive restriction enzymes (Fig. 4).

View larger version (33K):
[in this window]
[in a new window]
|
FIG. 5.
Map of 408 bp from the SV40 early promoter region
flanking the gpt coding region in G10 and G12 transgenic
cell lines. CpG dinucleotides are underlined. The numbers above the CpG
sites correspond to the methylation map data in Table 3. Bold numbers
represent the sites that were methylated or partially methylated in the
genomes of five out of the eight variants that were examined. The
arrows indicate the sequences used for the primer design. (The primers
were constructed after the bisulfite conversion reaction had been taken
into account.)
|
|
View this table:
[in this window]
[in a new window]
|
TABLE 3.
CpG-methylated, nonmethylated, and partially methylated
sites in the SV40 early promoter region of 5-AzaC-induced
6-TGr variants derived from the G10 and G12
cell linesa
|
|
The 10 common sites that were methylated or partially methylated in
five out of eight variants are marked on Fig. 5. Each of these
genomic methylation patterns resulted in transgene silencing, and all were induced by the demethylation drug, 5-AzaC.
Reversion assays with 3 µM 5-AzaC were performed in the A3, A11, A13,
and A21 cell lines, as described in detail previously (22),
in order to check if the transgene was still potentially functional and
inactivated only by its epigenetic status. The high reversion
frequencies (6 × 10
4, 10 × 10
4,
60 × 10
4, and 500 × 10
4,
respectively) further emphasized the correlation between the methylation state and the silencing of the transgene. The control cell
lines that were used for these assays were the N37 nickel-induced variant, which was shown to be highly methylated in the gpt
locus and gave high reversion frequencies (6 × 10
4), and the N126 cell line, in which the gpt
gene is mutated. In this cell line no reversion was observed with
5-AzaC treatment (22). The spontaneous reversion rates for
methylated variants in these experiments were on the order of 3 × 10
6.
Changes in chromatin structure in the gpt locus of the
5-AzaC-induced variants.
To study whether the
observed changes in DNA methylation were correlated with
changes in the chromatin structure in the gpt locus, DNase I
sensitivity was examined in isolated nuclei from different
variant cell lines. As shown in Fig.
6, the variant clones of both G12 and G10
exhibited marked resistance to increasing concentrations of DNase I
compared with that in the parental G10 and G12 cell lines. The N37 cell
line was used as a positive control (Table 3). These data indicated a
more condensed chromatin structure of the transgene, induced as a
consequence of 5-AzaC treatment.

View larger version (51K):
[in this window]
[in a new window]
|
FIG. 6.
Resistance of 5-AzaC-induced 6TG-resistant clones to
DNase I. Nuclei isolated from G12, N37, A13, A14, and A15 cells (A) and
G10, A2, A6, and A7 cells (B) were treated with 0, 0.5, 1, 2, and 10 U
of DNase I. PCRs were performed on 50 ng of DNase I-digested DNA. PCR
products were separated on 1.2% agarose gels and stained with EtBr.
The expected gpt product is 561 bp. M, molecular weight
markers.
|
|
 |
DISCUSSION |
Our results showed that treatment of G10 and G12 transgenic cell
lines with 5-AzaC resulted in an unusually high frequency of 6-TG
resistant variants (1.5 × 10
2 to 4.5 × 10
2). Other studies (for examples, see references
24 and 33) showed 5-AzaC-induced
6-TG and TFT resistance in AS52 (33) and L5178Y cell lines
(24). In those studies the mutation frequency levels were
lower than the results presented here. This was probably due to the
shorter 5-AzaC treatment periods that were used in the two
mentioned studies (4 to 5 h compared to 48 h here). However, 5-AzaC is more effective at lowering DNA methylation with longer treatment periods (i.e., at least one cell cycle), and this is usually
the way cells are treated with this drug.
Detailed molecular analysis of the variants demonstrated that
transgene silencing by de novo DNA methylation was the major factor
responsible for this high level of 6-TG resistance. Transgene silencing
is a well-known phenomenon (7, 28), but it was unexpectedly
observed after treatment with the classical demethylation agent,
5-AzaC. Transgenes are probably recognized in cells by the specific
bacterial or viral sequences that they contain and their different
structures in the chromosomal environment (11, 28),
and by some unknown mechanism, 5-AzaC caused these transgenes to become silenced by inducing de novo DNA methylation and increased chromatin condensation. It is important to emphasize that the variant
cells were isolated after drug selection. As a result of 5-AzaC
treatment for 2 days, the transgene was probably demethylated. Then the
cells were grown in regular medium for a 7-day expression period (10 to
14 cell divisions). After this period, the majority of the nuclei did
not contain 5-AzaC (12). When the cells were transferred to
the selection media (6-TG), the selection was toward cells that could
inactivate the transgene. It is possible that part of the
6-TGr cell lines was a result of mutation (like the A5 and
A6 cell lines and also the A18 cell line), but the high frequency of
variants obtained supports a more general process of gene inactivation by methylation of cytosines in DNA. An equivalent model for silencing and reactivation of recombinant viral genes has recently been suggested
(4). According to this model, a host protein or protein complex binds to viral sequences and recruits a histone deacetylase to
the site. The enzyme deacetylates histones H3 and H4, resulting in a
more condensed chromatin structure and inhibition of transgene transcription. A direct relationship between DNA methylation and histone deacetylation was shown by Nan et al. (26). It is
possible that the same events happened in our system, due to the
selection conditions, leading to DNA methylation and chromatin
condensation of the gpt locus (16).
The reason for the higher frequency of G10 variants, compared to G12
variants, may be the different chromosomal localizations of the
gpt gene. In the G10 cells it was localized in a euchromatic region on chromosome 6, which might be more susceptible to protein binding and modifying enzymes, such as DNA methyltransferase, than the
gpt locus in G12 cells, which was located in close proximity to a condensed heterochromatic region near the telomere on chromosome 1.
The methylation maps of the different variants are not equal, but among
the 18 tested sites, there were 10 sites (Table 3) completely or
partially methylated in five out of the eight cell lines examined. It
was already demonstrated that the discrimination between methylated and
unmethylated alleles may be attributed to differences in methylation of
a very short and specific region (8, 10); thus, it is
possible that methylation of only a few critical sites was sufficient
to silence the gpt gene. To emphasize the relation between
the transgene silencing and methylation, reactivation of the transgene
silenced by 5-AzaC was performed with 5-AzaC again. The high reversion
frequencies suggested additional evidence for the epigenetic effect
induced by 5-AzaC.
The results we report here demonstrated that under specific conditions
5-AzaC may induce transgene silencing by DNA methylation and chromatin
condensation. Isolation of the specific regulatory protein(s) that
enhanced transgene silencing and the elucidation of its expression
pattern may be a useful tool for a controlled transgene inactivation
process. Further study of this phenomenon may help treat disease
involving viral integration and assist us in designing better
strategies for gene therapy.
This work was supported by grants ES05512 and ES00260 from the
National Institute of Environmental Health Sciences and
grant CA16037 from the National Cancer Institute.
| 1.
|
Amacher, D., and G. Turner.
1987.
The mutagenicity of 5-azacytidine and other inhibitors of replicative DNA synthesis in the L5178Y mouse lymphoma cell.
Mutat. Res.
176:123-131[Medline].
|
| 2.
|
Bender, C. M.,
M. M. Pao, and P. A. Jones.
1998.
Inhibition of DNA methylation by 5-aza-2'-deoxycytidine suppresses the growth of human tumor cell lines.
Cancer Res.
58:95-101[Abstract/Free Full Text].
|
| 3.
|
Call, K.,
J. Jensen,
H. Liber, and W. Thilly.
1986.
Studies of mutagenicity and clastogenicity of 5-azacytidine in human lymphoblasts and Salmonella typhimurium.
Mutat. Res.
160:249-257[Medline].
|
| 4.
|
Chen, W. Y.,
E. C. Bailey,
S. L. McCune,
J.-Y. Dong, and T. M. Townes.
1997.
Reactivation of silenced, virally transduced genes by inhibitors of histone deacetylase.
Proc. Natl. Acad. Sci. USA
94:5798-5803[Abstract/Free Full Text].
|
| 5.
|
Clark, S. J.,
J. Harrison,
C. L. Paul, and M. Frommer.
1994.
High sensitivity mapping of methylated cytosines.
Nucleic Acids Res.
22:2990-2997[Abstract/Free Full Text].
|
| 6.
|
Friedman, S.
1979.
The effect of 5-azacytidine on E. coli DNA methylase.
Biochem. Biophys. Res. Commun.
89:1328-1333[Medline].
|
| 7.
|
Gebara, M. M.,
C. Drevon,
S. A. Harcourt,
H. Steingrimsdottir,
M. R. James,
J. F. Burke,
C. F. Arlett, and A. R. Lehmann.
1987.
Inactivation of a transfected gene in human fibroblasts can occur by deletion, amplification, phenotypic switching, or methylation.
Mol. Cell. Biol.
7:1459-1464[Abstract/Free Full Text].
|
| 8.
|
Herman, J. G.,
J. R. Graff,
S. Myohanen,
B. D. Nelkin, and S. B. Baylin.
1996.
Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.
Proc. Natl. Acad. Sci. USA
93:9821-9826[Abstract/Free Full Text].
|
| 9.
|
Herman, J. G.,
F. Latif,
Y. Weng,
M. I. Lerman,
B. Zbar,
S. Liu,
D. Samid,
D.-S. Duan,
J. R. Gnarra,
W. M. Linehan, and S. B. Baylin.
1994.
Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma.
Proc. Natl. Acad. Sci. USA
91:9700-9704[Abstract/Free Full Text].
|
| 10.
|
Herman, J. G.,
A. Merlo,
L. Mao,
R. G. Lapidus,
J.-P. J. Issa,
N. E. Davidson,
D. Sidransky, and S. B. Baylin.
1995.
Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers.
Cancer Res.
55:4525-4530[Abstract/Free Full Text].
|
| 11.
|
Jahner, D.,
H. Stuhlmann,
C. L. Stewart,
K. Harbers,
J. Lohler,
I. Simon, and R. Jaenisch.
1982.
De novo methylation and expression of retroviral genomes during mouse embryogenesis.
Nature
298:623-628[Medline].
|
| 12.
|
Jones, P. A., and S. M. Taylor.
1980.
Cellular differentiation, cytidine analogs and DNA methylation.
Cell
20:85-93[Medline].
|
| 13.
|
Jones, P. A.,
S. M. Taylor,
T. Mohandas, and L. J. Shapiro.
1982.
Cell cycle-specific reactivation of an inactive X-chromosome locus by 5-azadeoxycytidine.
Proc. Natl. Acad. Sci. USA
79:1215-1219[Abstract/Free Full Text].
|
| 14.
|
Jutterman, R.,
E. Li, and R. Jaenisch.
1994.
Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation.
Proc. Natl. Acad. Sci. USA
91:11797-11801[Abstract/Free Full Text].
|
| 15.
|
Kargacin, B.,
C. B. Klein, and M. Costa.
1993.
Mutagenic responses of nickel oxides and nickel sulfides in Chinese hamster V79 cell lines at the xanthine guanine phosphoribosyl transferase locus.
Mutat. Res.
300:63-72[Medline].
|
| 16.
|
Kass, S. U.,
D. Pruss, and A. P. Wolfe.
1997.
How does DNA methylation repress transcription?
Trends Genet.
13:444-449[Medline].
|
| 17.
|
Kautiainen, T. L., and P. A. Jones.
1986.
DNA methyl-transferase levels in tumorigenic and nontumorigenic cells in culture.
J. Biol. Chem.
261:1594-1598[Abstract/Free Full Text].
|
| 18.
|
Kizaki, H.,
Y. Ohnishi,
Y. Azuma,
Y. Mizuno, and F. Ohsaka.
1992.
1- -D-Arabinosylcytosine and 5-azacytidine induce internucleosomal DNA fragmentation and cell death in thymocytes.
Immunopharmacology
24:219-227[Medline].
|
| 19.
|
Klein, C. B., and T. G. Rossman.
1990.
Transgenic Chinese hamster V79 cell lines which exhibit variable levels of gpt mutagenesis.
Environ. Mol. Mutagen.
16:1-12[Medline].
|
| 20.
|
Klein, C. B.,
L. Su,
T. G. Rossman, and E. T. Snow.
1994.
Transgenic gpt+ V79 cell lines differ in their mutagenic response to clastogens.
Mutat. Res.
304:217-228[Medline].
|
| 21.
|
Klein, C. B.,
L. Su,
J. Singh, and E. T. Snow.
1997.
Characterization of gpt deletion mutations in transgenic Chinese hamster cell lines.
Environ. Mol. Mutagen.
30:418-428[Medline].
|
| 22.
|
Lee, Y.-W.,
C. B. Klein,
B. Kargacin,
K. Salnikow,
J. Kitahara,
K. Dowjat,
A. Zhitkovich,
N. T. Christie, and M. Costa.
1995.
Carcinogenic nickel silences gene expression by chromatin condensation and DNA methylation: a new model for epigenetic carcinogens.
Mol. Cell. Biol.
15:2547-2557[Abstract].
|
| 23.
|
Lehmann, A. R.,
C. F. Arlett,
S. A. Harcourt,
H. Steingrimsdottir, and M. M. Gebara.
1989.
Mutagenic treatments result in inactivation of expression of a transfected bacterial gene integrated into a human cell line.
Mutat. Res.
220:255-262[Medline].
|
| 24.
|
McGregor, D. B.,
A. G. Brown,
P. Cattanach,
W. Shepherd,
C. Riach,
D. S. Daston, and W. J. Caspary.
1989.
TFT and 6-TG resistance of mouse lymphoma cells to analogs of azacytidine.
Carcinogenesis
10:2003-2008[Abstract/Free Full Text].
|
| 25.
|
Mulligan, R. C., and P. Berg.
1980.
Expression of a bacterial gene in mammalian cells.
Science
209:1422-1427[Abstract/Free Full Text].
|
| 26.
|
Nan, X.,
H.-H. Ng,
C. A. Johnson,
C. D. Laherty,
B. M. Turner,
R. N. Eisenman, and A. Bird.
1998.
Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex.
Nature
393:386-389[Medline].
|
| 27.
|
Ottaviano, Y. L.,
J.-P. Issa,
F. F. Parl,
H. S. Smith,
S. B. Baylin, and N. E. Davidson.
1994.
Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells.
Cancer Res.
54:2552-2555[Abstract/Free Full Text].
|
| 28.
|
Palmer, T. D.,
G. J. Rosman,
W. R. A. Osborne, and D. A. Miller.
1991.
Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes.
Proc. Natl. Acad. Sci. USA
88:1330-1334[Abstract/Free Full Text].
|
| 29.
|
Parrow, V. C.,
P. Alestrom, and K. M. Gautvik.
1989.
5-Azacytidine induced alterations in the GH12C1 cells: effects on cellular morphology, chromosome structure, DNA and protein synthesis.
J. Cell Sci.
93:533-543[Abstract/Free Full Text].
|
| 30.
|
Podger, D. M.
1983.
Mutagenicity of 5-azacytidine in Salmonella typhimurium.
Mutat. Res.
121:1-6[Medline].
|
| 31.
|
Santi, D. V.,
A. Norment, and C. E. Garrett.
1984.
Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine.
Proc. Natl. Acad. Sci. USA
81:6993-6997[Abstract/Free Full Text].
|
| 32.
|
Singal, R.,
R. Ferris,
J. A. Little,
S. Z. Wang, and G. D. Ginder.
1997.
Methylation of the minimal promoter of an embryonic globin gene silences transcription in primary erythroid cells.
Proc. Natl. Acad. Sci. USA
94:13724-13729[Abstract/Free Full Text].
|
| 33.
|
Spencer, D. L.,
W. J. Caspary,
K. C. Hines, and K. R. Tindall.
1996.
5-Azacytidine-induced 6-thioguanine resistance at the gpt locus in AS52 cells: cellular response.
Environ. Mol. Mutagen.
28:100-106[Medline].
|
| 34.
|
Taylor, S. M., and P. A. Jones.
1979.
Multiple new phenotypes induced in 10T1/2 and 3T3 cells treated with 5-azacytidine.
Cell
17:771-779[Medline].
|
| 35.
|
Yoshiura, K.,
Y. Kanai,
A. Ochiari,
Y. Shimoyama,
T. Sugimura, and S. Hirohashi.
1995.
Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas.
Proc. Natl. Acad. Sci. USA
92:7416-7419[Abstract/Free Full Text].
|
| 36.
|
Zimmermann, F. K., and I. Scheel.
1984.
Genetic effects of 5-azacytidine in Saccharomyces cerevisiae.
Mutat. Res.
139:21-24[Medline].
|